TMO — Thermo Fisher Scientific Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Thermo Fisher Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	PRESS
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	39,211	44,915	42,857	42,879	44,556
Cost of Revenue
Gross Profit	19,638	18,971	17,100	17,702	18,508
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	29,950	36,548	35,998	35,542	36,810
Operating Profit	9,261	8,367	6,859	7,337	7,746
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,841	7,835	6,298	7,037	7,308
Provision for Income Taxes
Net Income After Taxes	7,732	7,132	6,014	6,380	6,761
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	7,725	6,950	5,995	6,335	6,703
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,725	6,950	5,995	6,335	6,704
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	21.9	18	16.7	17.4	18.6
Dividends per Share